Study of Ponsegromab for Pancreatic Cancer with Weight Loss
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread to other organs (metastatic).
- You have lost a significant amount of weight (at least 5% in the last 6 months or 2% with a low BMI) due to the cancer.
- You have completed at least one month of your first chemotherapy plan (either nab-paclitaxel + gemcitabine for 28 days or FOLFIRINOX for 4 weeks) and are about to start the next cycle.
- You are able to take care of yourself and do most daily activities (ECOG 0 or 1).
- You do not have heart failure or a significantly weakened heart pump, and your kidneys and liver are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ponsegromab to see if it can help stop weight loss in people with advanced lung cancer. It is given alongside your usual immunotherapy and may help you maintain your strength and quality of life.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new combination of a migraine drug (rimegepant) with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer. It aims to see if this combo can help shrink tumors or slow the cancer.
This study tests whether a drug already approved for other cancers can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight. The drug may help improve appetite and weight stability.
Hear when a new Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.